Fudan University: Prostatic Neoplasms trials

The registry lists 20 Prostatic Neoplasms studies with Fudan University as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 2 10No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• AI-Assisted Patient Support in mHSPCNot yet recruitingNCT07804030Not applicable
• SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPCRecruitingNCT07451795Phase 2
• CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate CancerNot yet recruitingNCT07268794Phase 2
• Study of HRS-2189 Combined HRS-5041 in Prostate CancerNot yet recruitingNCT06738745Phase 2
• Ivonescimab in the Treatment of Multiple Advanced TumorsRecruitingNCT06683846Phase 2
• Combination of TURP and Standard Systemic Therapy for MPCaRecruitingNCT06655259Phase 2
• Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)RecruitingNCT06251492Phase 2
• Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT TreatmentNot yet recruitingNCT05717582Phase 2
• Novel Therapy Target in Metastatic Prostate CancerRecruitingNCT05577689
• AI-LLM Communication Aid in Prostate Cancer Care (AI-CAP）Active, not recruitingNCT07082049Not applicable
• Heterogeneity of Tertiary Lymphoid Structures Predicts Distinct Malignancy and Immune Microenvironment in Prostate Cancer: a Retrospective Cohort StudyCompletedNCT06484127
• a Study of Combined mpMRI and PSMA PET/CT for Highly Suspicious Patients Performing Radical Prostatectomy Without BiopsyStatus unknownNCT05670691
• Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST TrialActive, not recruitingNCT05223582Phase 2
• Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerStatus unknownNCT05212857Phase 2
• Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA TrialStatus unknownNCT05188911
• The Effect of Information Support Program on Self-efficacy of Prostate Cancer Patients During Hormonal TherapyCompletedNCT04340713Not applicable
• Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the BoneStatus unknownNCT03988686Not applicable
• Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate CancerStatus unknownNCT03089099
• Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)Status unknownNCT02742675Phase 2
• Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate CancerStatus unknownNCT02723526